Silver Creek Pharmaceuticals, Inc.

Merrimack Pharmaceuticals, Inc.

Matthew D Onsum

Ulrik Bjerl Nielsen

Birgit Schoeberl

Brian Harms

Thomas Joseph Wickham

Byron DeLaBarre

Bryan Linggi

Yan Zhang

Shaun M Lippow

Laura D J Antipov

Timothy R Stowe

Andrea D Nickerson

Bjorn L Millard

Kristopher M Kuchenbecker

Shawdee Eshghi

Jonathan Basil Fitzgerald

William Kubasek

Francis David Gibbons

Byron Delabarre

Thomas Wickham

Laura DJ Antipov

Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue.

Method of treating skin tissue damage by topically administering a bi-specific protein comprising a human insulin-like growth factor variant and a human annexin A5 variant

Bi-specific therapeutic proteins, in vivo methods of use thereof and encoding nucleic acids thereof

Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to a target molecule; and (b) an activator domain that detectably modulates tissue regeneration.

Bi-specific fusion proteins

Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair damaged tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to an ischemia-associated molecule; and (b) an activator domain that that detectably modulates the activity of a cellular network.

Method of inhibiting apoptosis or promoting cell survival by providing a bi-specific protein comprising insulin-like growth factor IGF-1 and Annexin A5

Method of protecting tissue from damage by administering a bi-specific therapeutic protein comprising insulin-like growth factor 1 (IGF-1) and Annexin A5

Bi-specific annexin A5/IGF-1 proteins and methods of use thereof to promote regeneration and survival of tissue

Method of treating myocardial infarction by administering a bi-specific fusion protein

Bi-specific fusion proteins for tissue repair

The invention provides methods for treating patients which methods comprise methods for predicting responses of cells, such as tumor cells, to treatment with therapeutic agents. These methods involve measuring, in a sample of the cells, levels of one or more components of a cellular network and then computing a Network Activation State (NAS) or a Network Inhibition State (NIS) for the cells using a computational model of the cellular network. The response of the cells to treatment is then predicted124 based on the NAS or NIS value that has been computed. The invention also comprises predictive methods for cellular responsiveness in which computation of a NAS or NIS value for the cells (e.g., tumor cells) is combined with use of a statistical classification algorithm. Biomarkers for predicting responsiveness to treatment with a therapeutic agent that targets a component within the ErbB signaling pathway are also provided.

Methods and systems for predicting response of cells to a therapeutic agent

Growing community of inventors

El Cerrito, CA, United States of America

Matthew D Onsum